An Unbiased Ranking of Murine Dietary Models Based on Their Proximity to Human Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD 'human proximity score' to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that Western diets align closely with human MASH; high cholesterol content, extended study duration and/or genetic manipulation of disease-promoting pathways are required to intensify liver damage and accelerate significant (F2+) fibrosis development. Choline-deficient models rapidly induce MASH-fibrosis while showing relatively poor translatability. Our ranking of commonly used MASLD models, based on their proximity to human MASLD, helps with the selection of appropriate in vivo models to accelerate preclinical research.

Citing Articles

The effects of SGLT2 inhibitors on metabolic phenotype and FGF-21 expression from the adipose tissue and the liver are less pronounced in ob/ob mice.

Di Vincenzo A, Granzotto M, Crescenzi M, Fioretto P, Vettor R, Rossato M BMC Endocr Disord. 2025; 25(1):63.

PMID: 40059147 PMC: 11892253. DOI: 10.1186/s12902-025-01879-3.

Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment.

Byrne C, Armandi A, Pellegrinelli V, Vidal-Puig A, Bugianesi E Nat Rev Gastroenterol Hepatol. 2025; .

PMID: 39962331 DOI: 10.1038/s41575-025-01045-z.

Impact of Sexual Dimorphism on Therapy Response in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: From Conventional and Nutritional Approaches to Emerging Therapies.

Dileo E, Saba F, Parasiliti-Caprino M, Rosso C, Bugianesi E Nutrients. 2025; 17(3).

PMID: 39940335 PMC: 11821005. DOI: 10.3390/nu17030477.

Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity.

Hupa-Breier K, Schenk H, Campos-Murguia A, Wellhoner F, Heidrich B, Dywicki J Mol Metab. 2025; 93:102104.

PMID: 39855563 PMC: 11815970. DOI: 10.1016/j.molmet.2025.102104.

Endogenous C-type natriuretic peptide offsets the pathogenesis of steatohepatitis, hepatic fibrosis, and portal hypertension.

Perez-Ternero C, Li W, Aubdool A, Goldin R, Loy J, Devalia K PNAS Nexus. 2025; 4(1):pgae579.

PMID: 39816244 PMC: 11734523. DOI: 10.1093/pnasnexus/pgae579.

References

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

Poirier P, Giles T, Bray G, Hong Y, Stern J, Pi-Sunyer F . Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition,.... Circulation. 2005; 113(6):898-918. DOI: 10.1161/CIRCULATIONAHA.106.171016. View

Flegal K, Kit B, Orpana H, Graubard B . Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013; 309(1):71-82. PMC: 4855514. DOI: 10.1001/jama.2012.113905. View

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023; 78(6):1966-1986. PMC: 10653297. DOI: 10.1097/HEP.0000000000000520. View

Tiniakos D, Vos M, Brunt E . Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010; 5:145-71. DOI: 10.1146/annurev-pathol-121808-102132. View

Bedossa P . Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014; 60(2):565-75. DOI: 10.1002/hep.27173. View

Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A . Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. Gastroenterology. 2020; 158(7):1899-1912. DOI: 10.1053/j.gastro.2019.12.054. View

Hardy T, Oakley F, Anstee Q, Day C . Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annu Rev Pathol. 2016; 11:451-96. DOI: 10.1146/annurev-pathol-012615-044224. View

Anstee Q, Reeves H, Kotsiliti E, Govaere O, Heikenwalder M . From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019; 16(7):411-428. DOI: 10.1038/s41575-019-0145-7. View

10.

Asgharpour A, Cazanave S, Pacana T, Seneshaw M, Vincent R, Banini B . A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol. 2016; 65(3):579-88. PMC: 5012902. DOI: 10.1016/j.jhep.2016.05.005. View

11.

Bachmann A, Morel J, El Alam G, Rodriguez-Lopez S, de Lima T, Goeminne L . Genetic background and sex control the outcome of high-fat diet feeding in mice. iScience. 2022; 25(6):104468. PMC: 9167980. DOI: 10.1016/j.isci.2022.104468. View

12.

Farrell G, Schattenberg J, Leclercq I, Yeh M, Goldin R, Teoh N . Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis. Hepatology. 2018; 69(5):2241-2257. DOI: 10.1002/hep.30333. View

13.

Anstee Q . Animal models in nonalcoholic steatohepatitis research: utility and clinical translation. Liver Int. 2011; 31(4):440-2. DOI: 10.1111/j.1478-3231.2011.02463.x. View

14.

Santhekadur P, Kumar D, Sanyal A . Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 2017; 68(2):230-237. PMC: 5775040. DOI: 10.1016/j.jhep.2017.10.031. View

15.

Im Y, Hunter H, de Gracia Hahn D, Duret A, Cheah Q, Dong J . A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD. Hepatology. 2021; 74(4):1884-1901. DOI: 10.1002/hep.31897. View

16.

Gallage S, Barragan Avila J, Ramadori P, Focaccia E, Rahbari M, Ali A . A researcher's guide to preclinical mouse NASH models. Nat Metab. 2022; 4(12):1632-1649. DOI: 10.1038/s42255-022-00700-y. View

17.

Boland M, Oro D, Tolbol K, Thrane S, Nielsen J, Cohen T . Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol. 2019; 25(33):4904-4920. PMC: 6737317. DOI: 10.3748/wjg.v25.i33.4904. View

18.

Kampschulte M, Stockl C, Langheinrich A, Althohn U, Bohle R, Krombach G . Western diet in ApoE-LDLR double-deficient mouse model of atherosclerosis leads to hepatic steatosis, fibrosis, and tumorigenesis. Lab Invest. 2014; 94(11):1273-82. DOI: 10.1038/labinvest.2014.112. View

19.

Li L, Zhang G, Lee K, Lopez R, Previs S, Willard B . A Western diet induced NAFLD in LDLR(-/)(-) mice is associated with reduced hepatic glutathione synthesis. Free Radic Biol Med. 2016; 96:13-21. PMC: 5297627. DOI: 10.1016/j.freeradbiomed.2016.03.032. View

20.

Saito K, Uebanso T, Maekawa K, Ishikawa M, Taguchi R, Nammo T . Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis. Sci Rep. 2015; 5:12466. PMC: 4542161. DOI: 10.1038/srep12466. View